We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

This study has been terminated.
(Lack of efficacy. Stopped at first interim evaluation point)
ClinicalTrials.gov Identifier:
First Posted: June 1, 2006
Last Update Posted: March 20, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Auron Healthcare GmbH

The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced disease.

The primary evaluation criterion is clinical benefit response.

Condition Intervention Phase
Gastrointestinal Cancer Prostate Cancer Genital Neoplasms, Female Drug: AMT2003 Phase 2 Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomised, Multicenter Phase II/III Clinical Trial to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT Versus Placebo

Resource links provided by NLM:

Further study details as provided by Auron Healthcare GmbH:

Primary Outcome Measures:
  • Improvement in clinical benefit response [ Time Frame: Jan 2010 ]

Secondary Outcome Measures:
  • Progression free survival [ Time Frame: Jan 2010 ]
  • Overall survival [ Time Frame: Jan 2010 ]
  • Overall response rate [ Time Frame: 2010 ]
  • Duration of response [ Time Frame: January 2010 ]
  • Quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]) [ Time Frame: Jan 2010 ]
  • Safety and tolerability [ Time Frame: Jan 2010 ]

Enrollment: 67
Study Start Date: May 2006
Study Completion Date: March 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AMT2003 Drug: AMT2003

Detailed Description:

The study will include patients with a variety of solid tumors (i.e. esophageal, colon, pancreatic, bronchial, gastric, hepatocellular, gall bladder, prostate and gynaecological carcinomas.)

The clinical benefit response - CBR, is an end point that provides a clinical measure for symptom improvement in patients. The key evaluation parameters for CBR will be assessment of pain, the ability to perform daily activities and weight change.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cancer confirmed by histology or cytology
  • At least one measurable lesion
  • Advanced disease refractory to standard therapy or for which no standard therapy exists
  • Life expectancy at least 3 months

Exclusion Criteria:

  • Known secondary neoplasia or central nervous system (CNS) metastases, acute or chronic leukemia, lymphoma or multiple myeloma
  • Body weight below 45 kg
  • Female patients who are pregnant or breast feeding or adults of reproductive potential not employing effective birth control methods
  • Concurrent severe or uncontrolled medical disease
  • Acute or chronic liver disease
  • Confirmed diagnosis of HIV
  • Insulin dependent diabetes mellitus/abnormal glucose tolerance test (GTT)/latent diabetes mellitus type I or II
  • Chemotherapy or radiotherapy less than 4 weeks prior to entry
  • Surgery less than 2 weeks prior to entry (or not recovered from effects of surgery)
  • Participation in a clinical trial less than 30 days prior to entry into this study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00332280

Bosnia and Herzegovina
Klinicki Centar Univerziteta Sarajevo - Klinika za gastroenterohepatologiju
Sarajevo, Bosnia and Herzegovina
Clinic SanaFontis
Freiburg im Breisgau, Germany, 79111
Sponsors and Collaborators
Auron Healthcare GmbH
Principal Investigator: Joachim Drevs, PD Dr. Med Clinic SanaFontis
  More Information

Additional Information:
Responsible Party: Auron Healthcare GmbH
ClinicalTrials.gov Identifier: NCT00332280     History of Changes
Other Study ID Numbers: AMT/P2CA/001
First Submitted: May 31, 2006
First Posted: June 1, 2006
Last Update Posted: March 20, 2013
Last Verified: March 2013

Keywords provided by Auron Healthcare GmbH:
solid tumors
clinical benefit
quality of life
esophageal cancer
colon cancer
pancreatic cancer
gastric cancer
liver cancer
gall bladder cancer
prostate cancer
gynecological cancer
lung cancer
Tumors of GI tract, prostate and gynaecological

Additional relevant MeSH terms:
Prostatic Neoplasms
Gastrointestinal Neoplasms
Genital Neoplasms, Female
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases